Morphine Sulphate

Weekly News Recap
#Phispers

Stock Recap
#PipelineProspector

Virtual Booth

Contact Supplier

Access all COS suppliers
Check all USDMF suppliers

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

33 API Suppliers, 12 USDMF, 6 CEP/COS, 4 KDMF, 14 NDC API, 11 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

51 Drugs in Development

51 Drugs in Development

FINISHED DOSAGE FORMULATIONS

636 FDF Dossiers, 223 FDA Orange Book, 169 Europe, 49 Canada, 109 Australia, 22 South Africa, 64 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET, EXTENDED RELEASE;ORAL - 100MG, TABLET, EXTENDED RELEASE;ORAL - 15MG, TABLET, EXTENDED RELEASE;ORAL - 200MG, TABLET, EXTENDED RELEASE;ORAL - 30MG, TABLET, EXTENDED RELEASE;ORAL - 60MG, INJECTABLE;INJECTION - 1MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, INJECTABLE;INJECTION - 5MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, SOLUTION;INTRAMUSCULAR - 10MG/0.7ML (10MG/0.7ML), INJECTABLE;INJECTION - 10MG/ML, INJECTABLE;INJECTION - 15MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, INJECTABLE;INJECTION - 2MG/ML, INJECTABLE;INJECTION - 4MG/ML, INJECTABLE;INJECTION - 50MG/ML, INJECTABLE;INJECTION - 8MG/ML, CAPSULE, EXTENDED RELEASE;ORAL - 100MG, CAPSULE, EXTENDED RELEASE;ORAL - 10MG, CAPSULE, EXTENDED RELEASE;ORAL - 130MG, CAPSULE, EXTENDED RELEASE;ORAL - 150MG, CAPSULE, EXTENDED RELEASE;ORAL - 200MG, CAPSULE, EXTENDED RELEASE;ORAL - 20MG, CAPSULE, EXTENDED RELEASE;ORAL - 30MG, CAPSULE, EXTENDED RELEASE;ORAL - 40MG, CAPSULE, EXTENDED RELEASE;ORAL - 50MG, CAPSULE, EXTENDED RELEASE;ORAL - 60MG, CAPSULE, EXTENDED RELEASE;ORAL - 70MG, CAPSULE, EXTENDED RELEASE;ORAL - 80MG, TABLET, EXTENDED RELEASE;ORAL - 100MG, TABLET, EXTENDED RELEASE;ORAL - 15MG, TABLET, EXTENDED RELEASE;ORAL - 30MG, TABLET, EXTENDED RELEASE;ORAL - 60MG, TABLET, EXTENDED RELEASE;ORAL - 15MG, TABLET, EXTENDED RELEASE;ORAL - 30MG, TABLET, EXTENDED RELEASE;ORAL - 60MG, SOLUTION;ORAL - 100MG/5ML, SOLUTION;ORAL - 10MG/5ML, SOLUTION;ORAL - 20MG/5ML, TABLET;ORAL - 15MG, TABLET;ORAL - 30MG, CAPSULE, EXTENDED RELEASE;ORAL - 100MG;4MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE, EXTENDED RELEASE;ORAL - 20MG;0.8MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE, EXTENDED RELEASE;ORAL - 30MG;1.2MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE, EXTENDED RELEASE;ORAL - 50MG;2MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE, EXTENDED RELEASE;ORAL - 60MG;2.4MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE, EXTENDED RELEASE;ORAL - 80MG;3.2MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

2 EUROAPI, 12 Evonik, 4 Rochem International Inc, 18 SPI Pharma, 23 DKSH, 2 Pharm-RX Chemical, 4 Boai NKY Pharmaceuticals Ltd, 6 Gangwal Healthcare, 10 Nanjing Well Pharmaceutical, 2 Pfanstiehl, 13 Kirsch Pharma, 4 ACG Worldwide, 15 Actylis, 1 Aeon Procare, 2 Alcedo Pharmachem, 6 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 2 Ashland, 1 Avesta Pharma, 36 BASF, 1 Bioplus Life Sciences, 4 CD Formulation, 2 Clariant, 17 Corel Pharma Chem, 5 DFE Pharma, 1 Esteem Industries, 4 Finar, 12 Gangwal Chemicals, 14 Ideal Cures, 3 Ingredion Pharma Solutions, 26 Kerry, 1 Keval Exports, 4 Kima Chemical, 6 Lonza Capsugel, 18 Microlex e.U, 1 Nanjing Bold Chemical, 2 Nitika Pharmaceutical Specialities, 2 Nomisma Healthcare, 3 Novo Excipients, 2 Pharmatrans-Sanaq, 9 Pluviaendo, 2 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 2 Qualicaps, 27 Roquette, 15 Seppic, 6 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 2 Shijiazhuang Huaxu Pharmaceutical, 9 Sigachi Industries, 2 Silverline Chemicals, 3 The Dow Chemical Company, 1 Ulanqab Kema New Material, 2 Valens Pharmachem, 2 Vasa Pharmachem, 1 Vertellus, 1 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

91 Fillers, Diluents & Binders, 79 Coating Systems & Additives, 54 Controlled & Modified Release, 48 Thickeners and Stabilizers, 43 Parenteral, 39 Topical, 39 Solubilizers, 38 Direct Compression, 32 Granulation, 30 Taste Masking, 27 Film Formers & Plasticizers, 21 Lubricants & Glidants, 19 Chewable & Orodispersible Aids, 15 Co-Processed Excipients, 15 Disintegrants & Superdisintegrants, 13 Rheology Modifiers, 12 Emulsifying Agents, 9 Empty Capsules, 8 API Stability Enhancers, 7 Surfactant & Foaming Agents, 5 Coloring Agents, 4 Vegetarian Capsules, 1 Soft Gelatin

DIGITAL CONTENT

1 Data Compilation #PharmaFlow, 121 News #PharmaBuzz

GLOBAL SALES INFORMATION

26 US Medicaid Prescriptions, 186 Regulatory FDF Prices

MARKET PLACE

19 APIs, 19 FDF Dossiers

PATENTS & EXCLUSIVITIES

88 US Patents, 23 Health Canada Patents

REF. STANDARDS & IMPURITIES

2 EDQM, 9 Others

Xls

Filters

Company Name

Year

DEALS // DEV.

Country

Sponsor

Therapeutic Area

Study Phase

Deal Type

Product Type

Dosage Form

Lead Product

Target

Filters

Reset Filter

All Developments

Therapeutic Area by Lead Product

Study Phase by Lead Product

Company by Lead Product

Top Deals by Deal Size (USD bn)

Reset All

01

Ethypharm

France

CPhI WW Frankfurt

Booth #5.0D100

Ethypharm is an international Pharma company with European roots manufacturing and commercializing essential drugs all over the world.

Lead Product(s) : Morphine Sulfate

Therapeutic Area : Neurology

Study Phase : Approved FDF

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

DEALS_DEV

Ethypharm Gains EU Approval for Morphine Immediate Release Tablets

Details : Company received marketing authorisations (MA) for the 1st Immediate-Release orodispersible tablets of morphine, an opioid receptor agonist for the management of severe pain.

Product Name : Undisclosed

Product Type : Controlled Substance

Upfront Cash : Inapplicable

February 12, 2021

Lead Product(s) : Morphine Sulfate

Therapeutic Area : Neurology

Highest Development Status : Approved FDF

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

Virtual Booth

02

AstraZeneca

United Kingdom

Israel

Pharmaconex

Not Confirmed

Find Clinical Drug Pipeline Developments & Deals for Morphine Sulphate